Baylor Genetics provides clinical diagnostic genomics services, offering a comprehensive platform of genetic tests including whole genome sequencing, whole exome sequencing, RNA sequencing, chromosomal microarray analysis, and specialized assays. The company has performed over 4 million tests worldwide and operates as a joint venture between Baylor College of Medicine and HU Group Holdings, Inc.
The organization has nearly 50 years of operating history in genetic testing and has pioneered advances across multiple genomic technologies, from early chromosomal microarray work through contemporary whole genome sequencing and multiomics approaches. Its clinical interpretation team comprises PhDs, MDs, laboratory directors, and genetic counselors who translate genomic findings into actionable clinical decisions. The company holds accreditations from CLIA, CAP, and the New York State Department of Health.
Baylor Genetics serves patients, healthcare providers, and partners globally across several clinical domains: rare disease diagnostics, pediatric genetics, reproductive health, hereditary cancer testing, and metabolic disorder testing. The platform is designed to deliver clinically relevant diagnostic insights that inform treatment and management decisions across these specialties.
